(Q36054872)

11 August 2017

1 reference

title

Optimal care of lupus nephritis patients (English)

1 reference

11 August 2017

1 reference

M Jadoul

1

1 reference

11 August 2017

publication date

1 January 2005

1 reference

11 August 2017

1 reference

11 August 2017

volume

14

1 reference

11 August 2017

issue

1

1 reference

11 August 2017

page(s)

72-76

1 reference

Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2063OA

Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2063OA

Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2063OA

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2063OA

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2063OA

Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2063OA

Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2063OA

Intervening before the onset of Type 1 diabetes: baseline data from the European Nicotinamide Diabetes Intervention Trial (ENDIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2063OA

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2063OA

Retarding progression of chronic renal disease: the neglected issue of residual proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2063OA

Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2063OA

Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2063OA

2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2063OA

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2063OA

Clinical practice. Nondiabetic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2063OA

Differential effects of calcium antagonist subclasses on markers of nephropathy progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2063OA

Management of glomerular proteinuria: a commentary

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2063OA

The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2063OA

Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2063OA

Premature coronary-artery atherosclerosis in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2063OA

Lipid-lowering therapy. New and established agents reduce risk of cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2063OA

Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2063OA

Systemic lupus erythematosus and accelerated atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2063OA

Plasma homocysteine levels in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2063OA

Is folate a promising agent in the prevention and treatment of cardiovascular disease in patients with renal failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2063OA

Folate therapy and in-stent restenosis after coronary stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2063OA

Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2063OA

Excess morbidity in patients starting uremia therapy without prior care by a nephrologist

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2063OA

The timing of specialist evaluation in chronic kidney disease and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2063OA

Pathophysiology of Progressive Nephropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2063OA

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2063OA

10.1191/0961203305LU2063OA

21 January 2018

Identifiers

DOI

1 reference

release_h3yimmgwwjejbbckwhtng6uceu

11 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/h3yimmgwwjejbbckwhtng6uceu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference